Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Genital Diseases, Male 1Carcinoma 1

Interventions

padeliporfin 5Nivolumab 3entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2anlotinib 2alectinib 2Vemurafenib 2Sunitinib 2Radiosurgery 2Cyclophosphamide 2Cisplatin 2Aspirin 2Ascorbic Acid 2trametinib 1spartalizumab 1relatlimab 1pertuzumab 1pembrolizumab 1palladium-bacteriopheophorbide 1olaparib 1niraparib 1nintedanib 1montanide ISA 51 1lutetium Lu 177 dotatate 1guadecitabine 1genexol-PM 1durvalumab 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms by Site × palladium-bacteriopheophorbide × Clear all
NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡